Elanco Animal Health Incorporated reported second quarter 2025 financial results on August 7, 2025, exceeding expectations for revenue and adjusted EPS. The company delivered its eighth consecutive quarter of growth, with organic constant currency revenue accelerating to 8%, led by U.S. Pet Health at 11%.
Revenue for the quarter was $1,241 million, a 5% increase on a reported basis. Adjusted EPS was $0.26, surpassing consensus estimates, while adjusted EBITDA was $238 million. Elanco's net leverage ratio improved to 4.0x adjusted EBITDA at quarter-end, and the year-end net leverage target was further improved to 3.8x to 4.1x.
The company raised its full-year 2025 guidance, with revenue now expected between $4,570 million and $4,620 million, adjusted EBITDA between $850 million and $890 million, and adjusted EPS between $0.85 and $0.91. Elanco also increased its innovation revenue target, reflecting strong contributions from Credelio Quattro, Experior, AdTab, and Zenrelia, which are stabilizing its base portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.